BioCentury | May 1, 2020
Product Development

April 30 Quick Takes: Pfizer to co-develop Valneva’s Lyme disease vaccine; plus Aravive-WuXi Biologics, Siga-BARDA, Pear, Capricor

...$4.59 (190%) to $7 since disclosing Wednesday that all six patients with critical COVID-19 given CAP-1002...
...Borrelia outer surface protein A BioCentury Staff VLA15, VLA15-101 Oral TPOXX, oral tecovirimat (oral ST-246, oral Arestvyr, SIGA-246) reSET reSET-O CAP-1002 Valneva...
BioCentury | Apr 4, 2020
Product Development

COVID-19 roundup: FDA’s expanded access program for convalescent plasma; plus more funding from BARDA, tests from Eurofins, BD-BioGx, and more

...Capricor, Revive redirect candidates to COVID-19 Capricor Therapeutics Inc. (NASDAQ:CAPR) said it is providing CAP-1002...
...and T cells to begin repair processes. FDA is reviewing an expanded access IND for CAP-1002...
...agencies. Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Sandi Wong, Assistant Editor CAP-1002 Mayo...
BioCentury | Jul 16, 2019
Clinical News

July 15 Clinical Quick Takes: Zejula meets in Phase III for 1L ovarian cancer; plus Capricor, Avrobio and NIH

...interim data from the Phase II HOPE-2 trial to treat Duchenne muscular dystrophy showing that CAP-1002...
...A;GL-3 - Globotriaosylceramide; PARP - Poly(ADP-ribose) polymerase Sandi Wong, Staff Writer, and Mary Romeo, Assistant Editor Ad26.Mos4.HIV AVR-RD-01, avr-02 CAP-1002 Zejula...
BioCentury | Feb 8, 2019
Clinical News

Capricor resumes DMD trial, will seek funding

...Capricor Therapeutics Inc. (NASDAQ:CAPR) resumed dosing in the Phase II HOPE-2 trial of IV CAP-1002 for...
...on the trial to investigate a severe allergic reaction that occurred in a patient during CAP-1002...
...cash. CAP-1002 comprises allogeneic cardiosphere-derived stem cells. Capricor Therapeutics Inc. (NASDAQ:CAPR), Beverly Hills, Calif. Product: CAP-1002...
BioCentury | Jan 4, 2019
Clinical News

Capricor places DMD trial on hold

...Capricor Therapeutics Inc. (NASDAQ:CAPR) placed a hold on the Phase II HOPE-2 trial of IV CAP-1002...
...muscular dystrophy (DMD) to investigate a severe allergic reaction that occurred in a patient during CAP-1002...
...12. CAP-1002 comprises allogeneic cardiosphere-derived stem cells. Capricor Therapeutics Inc. (NASDAQ:CAPR), Beverly Hills, Calif. Product: CAP-1002...
BioCentury | Jan 19, 2018
Company News

Capricor and Cedars-Sinai expand cardiosphere deal

...that the terms of the original 2014 deal remain unchanged. Capricor is evaluating lead candidate CAP-1002...
...to treat myocardial infarction and the Phase I/II HOPE to treat DMD and DMD-associated cardiomyopathy. CAP-1002...
...Capricor Therapeutics Inc. (NASDAQ:CAPR), Beverly Hills, Calif. Cedars-Sinai Medical Center, Los Angeles, Calif. Business: Cardiovascular Allison Johnson CAP-1002 CAP-2003 Capricor...
BioCentury | Jul 28, 2017
Clinical News

FDA to allow limb function endpoint in Capricor's DMD trials

...CAP-1002 . This half, the company plans to start a Phase II trial of IV CAP-1002...
...from the Parent Project Muscular Dystrophy (PPMD) advocacy group (see BioCentury, June 15, 2015) . CAP-1002...
...to use data from the trial, expected in 2H19, to support an NDA submission. Jaime De Leon AVI-4658 CAP-1002 deflazacort Emflaza eteplirsen Exondys...
BioCentury | Jul 28, 2017
Clinical News

FDA to allow limb function endpoint in Capricor's DMD trials

...candidate CAP-1002. This half, the company plans to start a Phase II trial of IV CAP-1002...
...disease designation to CAP-1002 to treat DMD. Capricor Therapeutics Inc. (NASDAQ:CAPR), Beverly Hills, Calif. Product: CAP-1002...
...to treat DMD. Capricor Therapeutics Inc. (NASDAQ:CAPR), Beverly Hills, Calif. Product: CAP-1002 Business: Musculoskeletal Jaime De Leon CAP-1002 Capricor...
BioCentury | Jul 13, 2017
Company News

Janssen declines option to Capricor's CAP-1002, Capricor to start DMD trials

...unit of Johnson & Johnson (NYSE:JNJ) declined its option to develop and commercialize the biotech's CAP-1002...
...plans to start a double-blind, placebo-controlled Phase II trial to evaluate the effects of IV CAP-1002...
...Therapeutics Inc. (NASDAQ:CAPR), Beverley Hills, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Musculoskeletal Shannon Lehnbeuter CAP-1002 Capricor...
BioCentury | May 19, 2017
Clinical News

Capricor's CAP-1002 misses Phase I/II heart repair endpoint

...in 142 patients with residual cardiac dysfunction following a myocardial infarction (MI) showing that intracoronary CAP-1002...
...reductions in scar size in the placebo arm exceeded reductions seen in natural history data. CAP-1002...
...plans to reduce the scope of its operations in order to focus primarily on developing CAP-1002...
Items per page:
1 - 10 of 32